Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Group 1 - The core point of the article highlights the performance of the HuShen 300 Growth ETF managed by Huaxia Fund Management, which has seen a return of 28.50% since its inception on September 5, 2023, and a return of 3.61% over the past month [1][1][1] - As of the midday close on February 4, the HuShen 300 Growth ETF (159523) decreased by 0.31%, with a trading volume of 2.2597 million yuan [1][1][1] - The top holdings of the ETF include companies such as CATL, which rose by 1.58%, Kweichow Moutai, which increased by 2.01%, and Zijin Mining, which saw a slight increase of 0.05% [1][1][1] Group 2 - Other notable stock performances within the ETF include Sunlight Power, which fell by 0.27%, Haiguang Information, which dropped by 3.51%, and Heng Rui Pharmaceutical, which decreased by 2.14% [1][1][1] - The ETF's performance benchmark is the CSI Select 300 Growth Innovation Strategy Index return rate [1][1][1] - The fund manager is Zhao Zongting, indicating a specific leadership in the management of the ETF [1][1][1]

截至2026年2月4日 10:58，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.31%，恩华药业上涨1.62%，新和成上涨1.57%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达1890.95万元。（数据来源：Wind） 消息面上，阿斯利康宣布未来十年在中国投资150亿美元，重点投向细胞治疗与放射性偶联药物 （RDC）两大前沿方向，涵盖北京、上海的战略研发中心建设，以及无锡、泰州、青岛、北京等地生 产基地扩建与新建，并计划将中国高技能员工队伍扩展至超2万人。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本 ...

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced a decline, with a 2.00% drop on February 4, 2023, and a year-to-date decrease of 5.46% [1] - As of February 4, 2023, 恒瑞医药's stock price was reported at 56.32 yuan per share, with a total market capitalization of 373.07 billion yuan [1] - The company has seen a net outflow of 1.57 billion yuan in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - As of September 30, 2025, 恒瑞医药 reported a total of 397,300 shareholders, with an average of 16,058 circulating shares per shareholder [3] Group 3 - For the period from January to September 2025, 恒瑞医药 achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% year-on-year [3] - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in shareholding [4]

在供需宽松格局延续、市场价格承压运行的背景下，叠加国际地缘政治动荡、欧盟反倾销关税等贸易壁 垒加码，以及"双碳"目标下绿色转型政策的刚性引导，2026年国内己二酸行业正锚定绿色化、高端化方 向加速转型，在市场压力中挖掘结构性机遇。 供需宽松成定局 隆众资讯预测，2026年国内己二酸总产能将攀升至445.5万吨，总产量预计将稳定在277万吨左右，月度 产量呈缓幅上涨态势，波动区间维持在每月20万～25万吨。行业整体开工率预计在60%左右，处于历史 低位。 绿色转型拓新机 "下游尼龙66、聚对苯二甲酸-己二酸丁二醇酯(PBAT)、TPU等领域计划新增产能63.5万吨，而传统下游 浆料、鞋底原液等领域需求增量有限。若新增产能全部按时投产，按各产品对己二酸单耗核算，预计全 年可新增己二酸的消费量30万吨。"隆众资讯己二酸分析师阎晓雨表示。 2026年，己二酸行业处于政策引导、市场倒逼与技术驱动的关键转型期，环保与碳减排政策将持续推动 行业落后产能出清，产能集中度进一步提升。随着合成生物基技术突破，国内生物基己二酸产业化进程 加快，已进入万吨级示范验证期。其低碳环保特性在高端尼龙66、3D打印材料等新兴领域的应用渗透 ...

Core Viewpoint - The Shanghai 180 Index and its corresponding ETF have shown strong performance, with significant increases in key constituent stocks, indicating a positive market sentiment and potential investment opportunities in the Shanghai securities market [1][2]. Group 1: Index Performance - As of February 3, 2026, the Shanghai 180 Index rose by 1.40%, with notable gains from stocks such as JinkoSolar (up 13.27%) and Sany Heavy Industry (up 7.95%) [1]. - The Shanghai 180 ETF (530280) increased by 1.64%, with a latest price of 1.24 yuan, and has seen a cumulative rise of 1.81% over the past month [1]. - The ETF has a year-to-date maximum drawdown of 4.28%, with a relative benchmark drawdown of 0.06% [1]. Group 2: Liquidity and Trading Data - The Shanghai 180 ETF had a turnover rate of 0.78% during the trading session, with a transaction volume of 458,700 yuan [1]. - The average daily trading volume over the past year for the ETF was 159,160 yuan [1]. Group 3: Fund Metrics - The ETF has a Sharpe ratio of 2.08 since its inception as of January 30, 2026 [1]. - The management fee for the ETF is 0.15%, and the custody fee is 0.05% [1]. - The tracking error for the ETF over the past six months is 0.023% [1]. Group 4: Top Constituent Stocks - The top ten weighted stocks in the Shanghai 180 Index account for 24.85% of the index, with major contributors including Zijin Mining, Kweichow Moutai, and Ping An Insurance [2]. - The individual weightings of these stocks range from 4.22% for Kweichow Moutai to 1.79% for Industrial Fulian [3].

Core Insights - The report from Dongfang Securities highlights the significant commercial value of extrahepatic delivery technology, driven by MNCs' increasing interest and the rapid development of domestic companies in multi-target drugs and extrahepatic delivery platforms [1][2][3] Group 1: Market Dynamics - Frequent transactions in small nucleic acids indicate rising global recognition of domestic drugs, exemplified by recent strategic collaborations involving Shengyin Biotech and major pharmaceutical companies like Eli Lilly and Roche, which include upfront payments and milestone payments totaling up to $12 billion and $15 billion respectively [1] - MNCs are shifting focus from liver-targeted delivery technologies to extrahepatic delivery systems, targeting organs such as fat, muscle, central nervous system, heart, and kidneys, which could address significant unmet clinical needs [2] Group 2: Domestic Innovation - Domestic companies have accumulated substantial experience in chemical modifications and liver-targeted delivery technologies for small nucleic acids, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [3] - The proactive development of extrahepatic delivery platforms and multi-target small nucleic acid drug platforms positions domestic firms at the forefront globally, attracting MNCs' interest [3] Group 3: Investment Opportunities - Potential investment targets include companies such as Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Chengdu Xian Dao, and others, which are positioned to benefit from the growing market for small nucleic acid drugs [4]

证券日报网讯 2月3日，恒瑞医药在互动平台回答投资者提问时表示，公司严格按照交易所相关规定， 根据已披露的股份回购方案进行股份回购，不存在违规情形。 （文章来源：证券日报） ...

Core Viewpoint - The board of directors of Heng Rui Medicine has announced a postponement of the board election, extending the terms of the current board members and senior management until February 1, 2026, to ensure governance stability and avoid disruptions in research and commercialization processes [1][7][16]. Group 1: Board and Management Changes - The current board of directors, including key executives such as Chairman Sun Piaoyang and President Dai Hongbin, will continue their roles until the new board is elected [3][12]. - The postponement of the board election may be influenced by factors such as strategic continuity, shareholder opinion coordination, and candidate selection [7][16]. - As of February 3, 2023, Heng Rui Medicine's A-share price was 57.47 yuan, with a market capitalization of 381.44 billion yuan, while its Hong Kong stock price was 67 HKD, with a market capitalization of 444.69 billion HKD [7][16]. Group 2: Financial Performance and Business Development - In the first three quarters of 2024 and 2025, Heng Rui Medicine reported revenues of 27.985 billion yuan and 23.188 billion yuan, representing year-on-year growth of 22.63% and 14.85%, respectively [8][17]. - The net profits for the same periods were 6.337 billion yuan and 5.751 billion yuan, with year-on-year increases of 47.28% and 24.50% [8][17]. - The company achieved significant revenue from its innovative drug business, with sales and licensing income of 9.561 billion yuan in the first half of 2025, accounting for 60.66% of total revenue [9][18]. Group 3: Market Position and Competitive Landscape - Despite strong growth, Heng Rui Medicine faces challenges from competitors, particularly in the innovative drug sector, where it must contend with similar products from other companies [10][21]. - The company’s overseas revenue was approximately 716 million yuan in 2024, constituting only 2.86% of total revenue, highlighting a significant gap compared to competitors like BeiGene, which had over 60% of its revenue from international markets [9][18]. - The oncology segment remains the largest revenue source for Heng Rui Medicine, generating approximately 14.587 billion yuan in 2024, with a gross margin of 92.57% [19][20].

Core Viewpoint - Heng Rui Medicine (600276) has received a confirmation letter from the FDA regarding the acceptance of its biologics license application for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma patients [1] Group 1: Company Updates - The FDA has accepted the biologics license application for Carrelizumab, indicating progress in the company's drug development pipeline [1] - The total R&D investment for Carrelizumab-related projects has reached approximately 319.74 million yuan (unaudited) [1] Group 2: Industry Context - Several PD-1 monoclonal antibodies have been approved and are available in the market, including Pembrolizumab (Merck, brand name Keytruda), Nivolumab (Bristol-Myers Squibb, brand name Opdivo), Cemiplimab (Regeneron Pharmaceuticals, brand name Libtayo), and Dostarlimab (GlaxoSmithKline, brand name Jemperli) [1] - The global sales of anti-PD-1 antibodies are projected to reach approximately $41.546 billion in 2024 [1]